Chimera solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program of the immune system.
Chimera Bioengineering has raised $7.5M in total funding. The most recent round was Grant. The last funding was announced in April 2022.
Chimera Bioengineering's investors include Kairos Ventures, Sand Hill Angels, Life Science Angels, The Angels' Forum, Asian Fund For Cancer Research.
Chimera Bioengineering is headquartered in South San Francisco, United States.
Chimera solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program of the immune system.
Chimera Bioengineering is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Chimera Bioengineering — Funding & Investors." VCBacked, April 28, 2022, https://www.vcbacked.co/company/chimera-bioengineering. Accessed August 13, 2026.
VCBacked. (2022). Chimera Bioengineering — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/chimera-bioengineering
{{cite web |title=Chimera Bioengineering — Funding & Investors |url=https://www.vcbacked.co/company/chimera-bioengineering |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated